Drug Trial Radar · NCT03971370
Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .
Last checked: Nov 20, 2026Latest source record: Jun 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,800
Actual
Start
Sep 10, 2017
Primary completion
Sep 29, 2018
Study completion Feb 22, 2019
Sponsor
- Lead sponsor
- Jiangsu Province Centers for Disease Control and PreventionResearch network
- Sponsor type
- Research network
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 10 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals. The WHO clearly states that human diploid cell rabies vaccine is the "gold standard" rabies vaccine, because of no carcinogenicity and any foreign animal impurity or neurotoxicity factor. China does not approve the import of foreign HDCV and has insufficiency domestic HDCV, so this clinic trial was to assess the immunogenicity and safety of HDCV in healthy population for the large-scale developing of a lyophilized and purified HDCV.
Conditions
- Adverse Effect and Immunogenicity of Vaccine
Interventions
Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)Biological
Essen post-exposure immunization schedule at day 0,3,7,14,28.
Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)Biological
Zagreb post-exposure immunization schedule at day 0,7,21.
Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)Biological
Essen post-exposure immunization schedule at day 0,3,7,14,28.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate immunogenicity after the first doseTime frame: 14 days following the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial Center for Diseases Control and Prevention
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.